CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00570401
NCT00570401Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib

Memorial Sloan Kettering Cancer Center·interventional·Posted Dec 10, 2007·Updated Jan 22, 2016

In Brief

A Phase 2 clinical trial evaluating dasatinib for Lung Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that is no longer responding to erlotinib or gefitinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2007
Enrollment StartJun 1, 2006
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.6 years ago

Interventions

dasatinibdrug